Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer

LESSONS LEARNED: Studies targeting the androgen receptor (AR) signaling pathway in aromatase inhibitor (AI)‐resistant breast cancer are limited. Bicalutamide, one of the commonly used AR inhibitors in prostate cancer, in combination with AI, did not show synergistic activity in patients with estroge...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Qianyi, Xia, Wen, Lee, Kaping, Zhang, Jingmin, Yuan, Huimin, Yuan, Zhongyu, Shi, Yanxia, Wang, Shusen, Xu, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964139/
https://www.ncbi.nlm.nih.gov/pubmed/31434793
http://dx.doi.org/10.1634/theoncologist.2019-0564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964139/
https://www.ncbi.nlm.nih.gov/pubmed/31434793
http://dx.doi.org/10.1634/theoncologist.2019-0564

Ejemplares similares